InflaRx Announces Presentation at J.P. Morgan Healthcare Conference and Other Investor Events
InflaRx N.V. (Nasdaq: IFRX) has announced its participation in key investor conferences, including the 40th Annual J.P. Morgan Healthcare Conference on January 13, 2022, and the H.C. Wainwright BioConnect Conference starting January 10, 2022. The company will also host a virtual R&D event on February 3, 2022, focused on vilobelimab for Hidradenitis Suppurativa, detailing study design and endpoints for its Phase III trial. InflaRx aims to develop innovative anti-inflammatory therapeutics targeting the complement system.
- Participation in high-profile investor conferences may enhance visibility and investor interest.
- Hosting a virtual R&D event on vilobelimab could provide valuable insights into clinical trial progress.
- None.
- Presentation at J.P. Morgan Healthcare Conference on January 13th
- Corporate presentation for H.C. Wainwright BioConnect Conference available online starting January 10th
- Company to host virtual R&D Event on vilobelimab in Hidradenitis Suppurativa on February 3rd
JENA, Germany, Jan. 05, 2022 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, today announced its participation at several investor events.
40th Annual J.P. Morgan Healthcare Conference: Prof. Niels C. Riedemann, Chief Executive Officer and Founder of InflaRx, will give a corporate presentation on Thursday, January 13th at 11:15 am EST (5:15 pm CET) followed by a 20-minute Q&A. A live audio webcast and replay of the presentation will be provided on the InflaRx website in the Investors - Events & Presentations section.
H.C. Wainwright virtual BioConnect Conference: A corporate presentation will be available on demand starting Monday, January 10th at 7:00 am EST (1:00 pm CET). A link to the presentation will be available on the InflaRx website in the Investors - Events & Presentations section.
Virtual R&D Event: InflaRx will host a virtual R&D event on Thursday, February 3rd at 8:30 am EST (2:30 pm CET). The event will provide insight on the development of vilobelimab in Hidradenitis Suppurativa, including details on the study design and novel endpoint for the Phase III trial in this indication. In addition to Company management, Christopher Sayed, MD, Associate Professor of Dermatology, University of North Carolina School of Medicine, Chapel Hill, NC, will be presenting. To participate in the conference call, participants may pre-register here and will receive a dedicated link and dial-in details to easily and quickly access the call.
About InflaRx N.V.:
InflaRx (Nasdaq: IFRX) is a clinical-stage biopharmaceutical company focused on applying its proprietary technology to discover and develop first-in-class or best-in-class, potent and specific inhibitors of C5a. Complement C5a is a powerful inflammatory mediator involved in the progression of a wide variety of autoimmune and other inflammatory diseases. InflaRx was founded in 2007, and the group has offices and subsidiaries in Jena and Munich, Germany, as well as Ann Arbor, MI, USA. For further information, please visit www.inflarx.com.
Contacts:
InflaRx N.V.
Jordan Zwick – Chief Strategy Officer
Jason Stewart – Strategy & Investor Relations
Email: IR@inflarx.de
Tel: +1 917-338-6523
MC Services AG
Katja Arnold, Laurie Doyle, Andreas Jungfer
Email: inflarx@mc-services.eu
Europe: +49 89-210 2280
US: +1-339-832-0752
FORWARD-LOOKING STATEMENTS
This press release contains forward-looking statements. All statements other than statements of historical fact are forward-looking statements, which are often indicated by terms such as “may,” “will,” “should,” “expect,” “plan,” “anticipate,” “could,” “intend,” “target,” “project,” “believe,” “estimate,” “predict,” “potential” or “continue” and similar expressions. Forward-looking statements appear in a number of places throughout this release and may include statements regarding our intentions, beliefs, projections, outlook, analyses and current expectations concerning, among other things, the impact of the COVID-19 pandemic on the Company; the timing and our ability to commence and conduct clinical trials; potential results from current or potential future collaborations; our ability to make regulatory filings, obtain positive guidance from regulators, and obtain and maintain regulatory approvals for our product candidates, including based on the modified HiSCR as the primary endpoint for the Company’s Phase III trial of vilobelimab in HS; our intellectual property position; our ability to develop commercial functions; expectations regarding clinical trial data; our results of operations, cash needs, financial condition, liquidity, prospects, future transactions, growth and strategies; the industry in which we operate; the trends that may affect the industry or us and the risks, uncertainties and other factors described under the heading “Risk Factors” in InflaRx’s periodic filings with the Securities and Exchange Commission. These statements speak only as of the date of this press release and involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Given these risks, uncertainties and other factors, you should not place undue reliance on these forward-looking statements, and we assume no obligation to update these forward-looking statements, even if new information becomes available in the future, except as required by law.
FAQ
When is InflaRx presenting at the J.P. Morgan Healthcare Conference?
What is the focus of InflaRx's virtual R&D event on February 3, 2022?
When will the H.C. Wainwright BioConnect Conference presentation be available?
What is the main therapeutic focus of InflaRx N.V.?
